Sci-Bytes : 2008 : 01.27.2008 - Hot Paper in Medicine
SCI-BYTES - WHAT'S NEW IN RESEARCH
Week of January 27, 2008
Hot Paper in Medicine
"Effect of rosiglitazone on the frequency of
diabetes
in patients with impaired glucose tolerance or impaired fasting glucose: a
randomised controlled trial," by the DREAM (Diabetes REduction
Assessment with ramipril and rosiglitazone Medication) Trial Investigators
[H.C. Gerstein, et al.], Lancet, 368(9541): 1096-1105,
23-29 September 2006.
[Corresponding address: Population Health Research Institute, Hamilton,
Ontario, Canada]
Abstract: "Background Rosiglitazone is a
thiazolidinedione that reduces insulin resistance and might preserve
insulin secretion. The aim of this study was to assess prospectively the
drug's ability to prevent type 2 diabetes in individuals at high risk of
developing the condition. Methods 5269 adults aged 30
years or more with impaired fasting glucose or impaired glucose tolerance,
or both, and no previous cardiovascular disease were recruited from 191
sites in 21 countries and randomly assigned to receive rosiglitazone (8 mg
daily; n=2365) or placebo (2634) and followed for a median of 3 years. The
primary outcome was a composite of incident diabetes or death.
Analyses were done by intention to treat.
Findings At the end of study, 59 individuals had dropped
out from the rosiglitazone group and 46 from the placebo group. 306 (11.6%)
individuals given rosiglitazone and 686 (26.0%) given placebo developed the
composite primary outcome (hazard ratio 0.40, 95%
CI 0.35-0.46; p<0.0001); 1330 (50.5%) individuals in the rosiglitazone
group and 798 (30.3%) in the placebo group became normoglycaemic
(1.71,1-57-1.87; p<0.0001). Cardiovascular event rates were much the
same in both groups, although 14 (0.5%) participants in the rosiglitazone
group and two (0.1%) in the placebo group developed heart failure (p=0.01).
Interpretation Rosiglitazone at 8 mg daily for 3 years
substantially reduces incident type 2 diabetes and increases the likelihood
of regression to normoglycaemia in adults with impaired fasting glucose or
impaired glucose tolerance, or both."
This 2006 report from The Lancet was cited 52
times in current journal articles indexed by Thomson Scientific
during September-October 2007. During that two-month period, only one other
medicine paper published in the last two years, aside from reviews,
collected a higher number of citations. Prior to the most recent bimonthly
count, citations to the paper have accrued as follows:
SOURCE:
Hot Papers Database (Included with a subscription to the print
newsletter
Science Watch®, available from
the
Research Services Group of
Thomson
Scientific. Packaged on a CD that is
mailed with each Science Watch issue, the Hot Papers
Database contains data on hundreds of highly cited papers published during
the last two years. User interface permits searching by author,
organization, journal, field, and more. Total citations, as well as
citations accrued during successive bimonthly periods, can be assessed and
graphed. An updated CD containing the most recent bimonthly data is mailed
with every new issue of Science Watch, six times a
year. The CD also includes an electronic version of the Science
Watch issue in HTML format, for personal desktop
access.
Sci-Bytes : 2008 : 01.27.2008 - Hot Paper in Medicine